TSC2 and renal cell carcinoma: In this study, we used chronic treatment with rapamycin on TSC1/TSC2-mutant tumor cell lines, including human BLCA, HCC, and AML, and mouse RCC, to generate rapamycin-persistent (RP) derivatives.